nach oben

Erschienen in:

29.06.2020 | COVID-19 | Original Article Zur Zeit gratis

Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada

verfasst von: Robert C. Grant, Coleman Rotstein, Geoffrey Liu, Leta Forbes, Kathy Vu, Roy Lee, Pamela Ng, Monika Krzyzanowska, David Warr, Jennifer Knox

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

People with cancer face an elevated risk of infection and severe sequelae from COVID-19. Dexamethasone is commonly used for antiemetic prophylaxis with systemic therapy for cancer. However, dexamethasone is associated with increased risk of viral and respiratory infections, and causes lymphopenia, which is associated with worse outcomes during COVID-19 infections. Our purpose was to minimize dexamethasone exposure during antiemetic prophylaxis for systemic therapy for solid tumors during the COVID-19 pandemic, while maintaining control of nausea and emesis.

Methods

We convened an expert panel to systematically review the literature and formulate consensus recommendations.

Results

No studies considered the impact of dexamethasone-based antiemetic regimens on the risk and severity of COVID-19 infection. Expert consensus recommended modifications to the 2019 Cancer Care Ontario Antiemetic Recommendations.

Conclusion

Clinicians should prescribe the minimally effective dose of dexamethasone for antiemetic prophylaxis. Single-day dexamethasone dosing is recommended over multi-day dosing for regimens with high emetogenic risk excluding high-dose cisplatin, preferably in combination with palonosetron, netupitant, and olanzapine. For regimens with low emetogenic risk, 5-HT₃ antagonists are recommended over dexamethasone.

Dong E, Du H, Gardner L (2020) An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 20:533–534. https://doi.org/10.1016/S1473-3099(20)30120-1CrossRefPubMedPubMedCentral

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21(3):335–337. https://doi.org/10.1016/S1470-2045(20)30096-6CrossRefPubMedPubMedCentral

Yu J, Ouyang W, Chua MLK, Xie C (2020) SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.0980

Zhao X, Zhang B, Li P, Ma C, Gu J, Hou P, Guo Z, Wu H, Bai Y (2020) Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv:2020.2003.2017.20037572. https://doi.org/10.1101/2020.03.17.20037572

Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M (2020) Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 31:894–901. https://doi.org/10.1016/j.annonc.2020.03.296CrossRefPubMed

National Institute for Health and Care Excellence (2020) COVID-19 rapid guideline: delivery of systemic anticancer treatments. https://www.nice.org.uk/guidance/ng161. Accessed 27 Mar 2020

American Society of Clinic Oncology (2020) COVID-19 Provider & Practice Information. https://www.asco.org/asco-coronavirus-information/provider-practice-preparedness-covid-19. Accessed 27 Mar 2020

ESMO (2020) COVID-19: supporting oncology professionals. https://www.esmo.org/newsroom/covid-19-and-cancer/supporting-oncology-professionals. Accessed 27 Mar 2020

BC Cancer (2020) COVID-19 Information for health professionals in cancer care. http://www.bccancer.bc.ca/health-professionals/clinical-resources/provincial-cancer-clinical-management-guidelines-in-pandemic-situation-(covid-19). Accessed 27 Mar 2020

10.

Ueda M, Martins R, Hendrie PC, McDonnell T, Crews JR, Wong TL, McCreery B, Jagels B, Crane A, Byrd DR, Pergam SA, Davidson NE, Liu C, Stewart FM (2020) Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Cancer Netw 18:1–4. https://doi.org/10.6004/jnccn.2020.7560CrossRef

11.

Cancer Care Ontaro (2020) Pandemic planning clinical guideline for patients with cancer. https://www.accc-cancer.org/docs/documents/cancer-program-fundamentals/oh-cco-pandemic-planning-clinical-guideline_final_2020-03-10.pdf. Accessed April 3, 2020

12.

Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff R, Nuhad IK, Chua MLK, Hotte SJ, Meyers BM, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C (2020) A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist. 25:e936–e945. https://doi.org/10.1634/theoncologist.2020-0213CrossRefPubMedPubMedCentral

13.

Penel N, Bonvalot S, Minard V, Orbach D, Gouin F, Corradini N, Brahmi M, Marec-Berard P, Briand S, Gaspar N, Llacer C, Carrere S, Dufresne A, Le Cesne A, Blay JY (2020) French sarcoma group proposals for management of sarcoma patients during COVID-19 outbreak. Ann Oncol 31:965–966. https://doi.org/10.1016/j.annonc.2020.03.308CrossRefPubMed

14.

Cancer Care Ontaro (2019) Antiemetic recommendations for chemotherapy-induced nausea and vomiting: a clinical practice guideline

15.

Fardet L, Petersen I, Nazareth I (2016) Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med 13(5):e1002024. https://doi.org/10.1371/journal.pmed.1002024CrossRefPubMedPubMedCentral

16.

Stuck AE, Minder CE, Frey FJ (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11(6):954–963. https://doi.org/10.1093/clinids/11.6.954CrossRefPubMed

17.

Wolfe F, Caplan L, Michaud K (2006) Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54(2):628–634. https://doi.org/10.1002/art.21568CrossRefPubMed

18.

Olnes MJ, Kotliarov Y, Biancotto A, Cheung F, Chen J, Shi R, Zhou H, Wang E, Tsang JS, Nussenblatt R, Consortium CHI (2016) Effects of systemically administered hydrocortisone on the human Immunome. Sci Rep 6:23002. https://doi.org/10.1038/srep23002CrossRefPubMedPubMedCentral

19.

Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46:846–848. https://doi.org/10.1007/s00134-020-05991-xCrossRefPubMed

20.

Poston JT, Patel BK, Davis AM (2020) Management of critically ill adults with COVID-19. JAMA. https://doi.org/10.1001/jama.2020.4914

21.

Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS (2019) Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2:CD010406. https://doi.org/10.1002/14651858.CD010406.pub3CrossRefPubMed

22.

Auyeung TW, Lee JS, Lai WK, Choi CH, Lee HK, Lee JS, Li PC, Lok KH, Ng YY, Wong WM, Yeung YM (2005) The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Inf Secur 51(2):98–102. https://doi.org/10.1016/j.jinf.2004.09.008CrossRef

23.

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240–3261. https://doi.org/10.1200/JCO.2017.74.4789CrossRefPubMed

24.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MECCC (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119–v133. https://doi.org/10.1093/annonc/mdw270CrossRefPubMed

25.

Gu YL, Xie JM, Ren J, Cao H, Wei JR, Chen C, Shao LN, Jiang GQ (2019) Dexamethasone-sparing regimen is an effective and safe alternative in overall antiemetic protection: a systematic review and meta-analysis. Medicine (Baltimore) 98(39):e17364. https://doi.org/10.1097/MD.0000000000017364CrossRef

26.

Celio L, Bonizzoni E, Zattarin E, Codega P, de Braud F, Aapro M (2019) Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. BMC Cancer 19(1):1268. https://doi.org/10.1186/s12885-019-6454-yCrossRefPubMedPubMedCentral

27.

Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y (2015) Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. Cancer Sci 106(7):891–895. https://doi.org/10.1111/cas.12675CrossRefPubMedPubMedCentral

28.

Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, Fabi A, Capobianco AM, Isa L, Cavanna L, Bertolini A, Bichisao E, Bajetta E, Italian Trials in Medical Oncology G (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 19(8):1217–1225. https://doi.org/10.1007/s00520-010-0941-7CrossRefPubMed

29.

Furukawa N, Kanayama S, Tanase Y, Ito F (2015) Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin. Support Care Cancer 23(11):3317–3322. https://doi.org/10.1007/s00520-015-2760-3CrossRefPubMed

30.

McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty KJ, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater DR, Blum RA (2003) Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74(1):17–24. https://doi.org/10.1016/S0009-9236(03)00066-3CrossRefPubMed

31.

Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21(6):1655–1663. https://doi.org/10.1007/s00520-012-1710-6CrossRefPubMed

32.

Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M, Tsugawa K, Kojima Y, Furuya N, Matsuzaki K, Fukuda M, Sugae S, Ohta I, Arioka H, Tokuda Y, Narui K, Tsuboya A, Suda T, Morita S, Boku N, Yamanaka T, Nakajima TE (2018) Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. J Clin Oncol 36(10):1000–1006. https://doi.org/10.1200/JCO.2017.74.4375CrossRefPubMed

33.

Italian Group for Antiemetic Research (1998) Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. J Clin Oncol 16(9):2937–2942. https://doi.org/10.1200/JCO.1998.16.9.2937CrossRef

34.

Dranitsaris G, Bouganim N, Milano C, Vandermeer L, Dent S, Wheatley-Price P, Laporte J, Oxborough KA, Clemons M (2013) Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. J Support Oncol 11(1):14–21. https://doi.org/10.1016/j.suponc.2012.05.001CrossRefPubMed

35.

Morrow GR, Roscoe JA, Hickok JT, Stern RM, Pierce HI, King DB, Banerjee TK, Weiden P (1998) Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park) 12(3 Suppl 4):32–37

36.

Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64(5):1117–1122. https://doi.org/10.1002/1097-0142(19890901)64:5<1117::aid-cncr2820640525>3.0.co;2-rCrossRefPubMed

Titel: Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada
verfasst von: Robert C. Grant
Coleman Rotstein
Geoffrey Liu
Leta Forbes
Kathy Vu
Roy Lee
Pamela Ng
Monika Krzyzanowska
David Warr
Jennifer Knox
Publikationsdatum: 29.06.2020
Verlag: Springer Berlin Heidelberg
Schlagwörter: COVID-19
Antiemetische Therapie
Nebenwirkungen
Erschienen in: Supportive Care in Cancer / Ausgabe 10/2020
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-020-05588-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

Body composition changes in patients with head and neck cancer under active treatment: a scoping review

Is intra-arterial hepatic chemotherapy painful?

Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin

The use of the Distress Thermometer and the Hospital Anxiety and Depression Scale for screening of anxiety and depression in Italian women newly diagnosed with breast cancer

Pain, fatigue and depression symptom cluster in survivors of prostate cancer

Exploring the role of oral microorganisms in the pathogenesis of mucositis by assessing their impact on metabolic activity and reproductive capacity of epithelial cells in vitro

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie